Autolus is an early commercial-stage biopharmaceutical company developing next-generation T cell therapies for cancer and autoimmune diseases using proprietary, modular T cell programming technologies. The company's lead product is a CD19-targeted CAR T cell therapy engineered with a fast off-rate binder to reduce toxicity while maintaining efficacy, and the company is advancing this therapy and other candidates across multiple indications including relapsed/refractory blood cancers, lupus nephritis, multiple sclerosis, and neuroblastoma. Autolus generates revenue from product sales and retains commercial rights to its candidates worldwide, while also receiving milestone payments and royalties from partnership agreements with BioNTech and University College London.